A Phase 1, Randomized, Double-Blind, Placebo-Controlled, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral LPM526000133 Fumarate Capsules (LY03017) in Healthy Adult Subjects.
Latest Information Update: 27 May 2025
At a glance
- Drugs LY 03017 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Luye Pharma Group
Most Recent Events
- 27 May 2025 New trial record